In an encouraging development for children with severe atopic dermatitis (AD), dupilumab, an interleukin-4 (IL-4) receptor alpha antagonist, has shown evidence of improving height outcomes. According to new findings presented by Prof. Alan Irvine (Trinity College Dublin, Ireland) at the 2024 EADV Congress during a late-breaking session, children aged 6–11 years with severe AD and […]

A new study, presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress, reveals the potential of semaglutide, a GLP-1 receptor agonist, in treating hidradenitis suppurativa (HS). This research suggests semaglutide, already approved for obesity and diabetes treatment, may reduce HS flare-ups and improve quality of life in obese patients. Learn how this promising therapy could mark a breakthrough in managing this chronic skin condition. Read the full study published in the British Journal of Dermatology."

We are deeply saddened to learn of the passing of Prof. Marcus Maurer, a highly esteemed expert who contributed significantly to touchDERMATOLOGY. Our hearts and deepest sympathies are with his family and close friends during this difficult time. His guidance, expert insights, and contributions to our platform have been invaluable. We feel privileged to have […]

The FDA has approved nemolizumab-ilto (Nemluvio; Galderma) for treating prurigo nodularis, a chronic skin condition characterized by intensely itchy nodules. Nemolizumab is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine that drives multiple disease mechanisms in prurigo nodularis

At ASCO 2024 in Chicago, some exciting breakthroughs in melanoma research were revealed. Researchers from around the world presented innovative studies and cutting-edge treatments that could significantly impact melanoma care. We have selected some of the most exciting data to highlight that could impact patient outcomes in the future.

The touchDERMATOLOGY team has carefully reviewed leading publications to present the highlights of the most intriguing and influential studies from leading journals.

Chronic Spontaneous Urticaria (CSU) is a distressing condition characterized by the spontaneous appearance of itchy wheals and angioedema, persisting for six weeks or longer. For many patients, the struggle to manage symptoms remains challenging despite the use of H1-antihistamines. However, recent advancements offer new hope. At the EAACI 2024 meeting in Valencia, Spain, groundbreaking data was presented on several promising new compounds. In this article, we share some of the latest developments.